Perseo Pharma

Executive Summary

Perseo Pharma is a Swiss preclinical-stage biotech focused on developing novel drug delivery technologies for metabolic diseases. Founded in 2022, the company leverages its proprietary platform to improve the treatment of conditions such as exocrine pancreatic insufficiency (EPI). In May 2024, Perseo and its collaborator Nestlé Health Science presented compelling preclinical data on their lead candidate PER301 at the Digestive Disease Week (DDW) conference. The data demonstrated the potential of PER301 to address limitations in current EPI therapies, highlighting enhanced stability and targeted delivery. The partnership with Nestlé Health Science not only validates the platform but also provides access to resources and expertise in metabolic and gastrointestinal health. As a young company, Perseo is still in the early stages of development, but the promising preclinical results and strategic alliance position it for significant progress in the near term. The company's focus on drug delivery for metabolic diseases addresses a large market with high unmet need, and the upcoming milestones will be critical in determining its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 clinical trial for PER301 in exocrine pancreatic insufficiency40% success
• Q2 2026Presentation of additional preclinical data at a major gastroenterology conference70% success
• TBDExpansion of partnership with Nestlé Health Science to include additional indications50% success